CBX

 Cascade submitted the IND application for a THR-β agonist, CS060304, as a treatment for NASH. The US FDA approved the application in February 2024. This is the second drug candidate for NASH patients, following the first clinical-stage FXR agonist, CS0159. FDA letter CS060304 The CS060304 target is the same as MGL-3196, a novel THR-β agonist developed by Cascade, with highly specific enrichment in liver tissue. Compared to Resmetirom, CS060304 demonstrates significantly positive preclinical data, particularly in improving NAS scores and fibrosis in NASH mouse models. It exhibits characteristics of low effective dosage, significant efficacy, and good tolerability. Its clinical trial approval is expected to provide NASH patients with a safe and effective potential treatment option, making it a potential best-in-class potent selective THR-β agonist. The clinical trial in China will  begin at the Peking Union Medical College Hospital  led by Professor Zhang Shuyang. From 2021, Cascade ha